Goldman Sachs
PMVP icon

Goldman Sachs’s PMV Pharmaceuticals PMVP Stock Holding History

Goldman Sachs’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Buy
136,994
+22,130
+19% +$28.4K ﹤0.01% 6219
2026
Q1 		$142K Sell
114,864
-12,177
-10% -$15.5K ﹤0.01% 6155
2025
Q4 		$159K Sell
127,041
-43,761
-26% -$58.6K ﹤0.01% 6102
2025
Q3 		$239K Buy
170,802
+75,729
+80% +$105K ﹤0.01% 5874
2025
Q2 		$101K Buy
95,073
+4,810
+5% +$4.72K ﹤0.01% 5815
2025
Q1 		$98.4K Sell
90,263
-30,982
-26% -$42.1K ﹤0.01% 5788
2024
Q4 		$183K Sell
121,245
-388,759
-76% -$616K ﹤0.01% 5667
2024
Q3 		$760K Sell
510,004
-298,740
-37% -$462K ﹤0.01% 4822
2024
Q2 		$1.31M Sell
808,744
-286,506
-26% -$517K ﹤0.01% 4266
2024
Q1 		$1.86M Buy
1,095,250
+292,375
+36% +$546K ﹤0.01% 3919
2023
Q4 		$2.49M Sell
802,875
-140,616
-15% -$372K ﹤0.01% 3755
2023
Q3 		$5.79M Buy
943,491
+304,446
+48% +$2.09M ﹤0.01% 2849
2023
Q2 		$4M Sell
639,045
-14,586
-2% -$76.4K ﹤0.01% 3296
2023
Q1 		$3.12M Buy
653,631
+45,681
+8% +$321K ﹤0.01% 3492
2022
Q4 		$5.29M Buy
607,950
+81,486
+15% +$869K ﹤0.01% 3117
2022
Q3 		$6.26M Buy
526,464
+49,530
+10% +$716K ﹤0.01% 2937
2022
Q2 		$6.8M Buy
476,934
+58,889
+14% +$857K ﹤0.01% 2854
2022
Q1 		$8.7M Buy
418,045
+168,803
+68% +$2.98M ﹤0.01% 2829
2021
Q4 		$5.76M Sell
249,242
-44,598
-15% -$1.08M ﹤0.01% 3272
2021
Q3 		$8.76M Buy
293,840
+138,463
+89% +$4.42M ﹤0.01% 2850
2021
Q2 		$5.31M Buy
155,377
+74,516
+92% +$2.49M ﹤0.01% 3288
2021
Q1 		$2.66M Buy
+80,861
New +$3.19M ﹤0.01% 3706
2020
Q4 		– Sell
-167,751
Closed -$5.96M – 5653
2020
Q3 		$5.96M Buy
+167,751
New +$6.17M ﹤0.01% 2755

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Goldman Sachs's PMVP Position: Q2 2026 in Review

Goldman Sachs increased its PMV Pharmaceuticals (PMVP) stake by 19% in Q2 2026, buying an estimated $28.4K and bringing the position to 136,994 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #6219.

Goldman Sachs first reported a position in PMVP in Q3 2020 and has held it in 23 quarters since. The position peaked at $8.76M in Q3 2021. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Goldman Sachs held 136,994 shares of PMV Pharmaceuticals worth $184K as of Q2 2026.
  • Goldman Sachs bought 22,130 PMV Pharmaceuticals shares in Q2 2026, an estimated $28.4K.
  • PMV Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6219 holding.
  • Goldman Sachs first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 23 quarters since.
  • Goldman Sachs's PMV Pharmaceuticals position peaked at $8.76M in Q3 2021.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.